Glioblastoma is relentless. This aggressive brain cancer affects over 300,000 people worldwide each year, and the standard chemotherapy drug temozolomide (TMZ) often loses its battle against the tumor's defenses. Now researchers have discovered something that might shift the odds: the time of day you receive the drug could matter as much as the drug itself.
The finding emerged from work published in the Journal of Neuro-Oncology, where scientists studying glioblastoma noticed something unexpected. The tumor's main defense mechanism—a DNA repair enzyme called MGMT—doesn't work at constant levels. Instead, it fluctuates throughout the day in a predictable rhythm, rising and falling like any other biological process governed by the body's circadian clock.
If MGMT levels follow a daily pattern, the researchers reasoned, then perhaps TMZ would be more effective at certain times too. They tested this hypothesis and found it held up: the drug works better in the morning, when MGMT activity is lower and the tumor's repair machinery is slower to respond.
We're a new kind of news feed.
Regular news is designed to drain you. We're a non-profit built to restore you. Every story we publish is scored for impact, progress, and hope.
Start Your News Detox"When we found that TMZ is more effective in the morning, we wondered if, perhaps, this coincides with when there is less MGMT around to repair TMZ-induced damage," explains researcher David Herzog. The team then built a mathematical model to pinpoint the optimal timing window—and discovered that dosing TMZ right after MGMT protein peaks gives the drug the longest, most effective window to work before the tumor's defenses strengthen again.
There's a practical wrinkle, though. Mathematician Olivia Walch points out that while the concept sounds straightforward, the execution gets complicated. "Dosing time can depend on a multitude of factors, including dose and individual variations in circadian rhythms," she notes. What works as a general principle in a model requires careful calibration in real patients.
The research also hints at something broader: the timing question might apply to other glioblastoma treatments too. The team is now investigating whether drugs like dexamethasone—used to control brain swelling—should also be timed strategically. Some treatments might inadvertently promote tumor growth at certain times of day, so avoiding those windows could matter as much as hitting the right ones.
This work represents an early step toward what's called chronomedicine: using the body's natural rhythms to improve treatment timing. For a disease as aggressive as glioblastoma, even small advantages compound. The next phase will be testing whether this timing approach actually improves outcomes in patients—moving from mathematical models to real clinical practice.
